News
NKTR
0.9342
+5.55%
0.0491
Weekly Report: what happened at NKTR last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at NKTR last week (0311-0315)?
Weekly Report · 03/18 09:24
Weekly Report: what happened at NKTR last week (0304-0308)?
Weekly Report · 03/11 09:24
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
TipRanks · 03/07 06:00
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
NASDAQ · 03/06 17:33
Nektar Therapeutics Is Maintained at Hold by Jefferies
Dow Jones · 03/06 14:54
Nektar Therapeutics Price Target Raised to $1.00/Share From $0.50 by Jefferies
Dow Jones · 03/06 14:54
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Benzinga · 03/06 14:44
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Arrivent Biopharma, Ferguson and Target among companies with revised targets. Ferguson, Target and Box are among the companies with new analyst coverage. Analysts raised their ratings on Arrivent, Ferguson, and Target.
Reuters · 03/06 06:47
Nektar Therapeutics reports results for the quarter ended in December - Earnings Summary
Nektar Therapeutics reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 22 cents per share. Revenue rose 8.5% to $23.89 million from a year ago. Nektar shares had risen by 59.3% this quarter.
Reuters · 03/05 23:30
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
NASDAQ · 03/05 15:07
Nektar Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $23.89M Beat $18.05M Estimate
Nektar Therapeutics reported quarterly losses of $0.22 per share. The company reported quarterly sales of $23.89 million. Nektar also beat the analyst consensus estimate of $18.05 million by 32.29%. The company's quarterly sales were up 8.45 percent over the same period last year.
Benzinga · 03/04 21:24
Nektar Therapeutics Q4 Loss decreases, but misses estimates
NASDAQ · 03/04 21:18
Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M
Q4 GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M. Nektar Therapeutics shares down 2.62% in after-hours trading. The company's cash and investments are expected to last into 2026.
Seeking Alpha · 03/04 21:17
*Nektar Therapeutics 4Q Rev $23.9M >NKTR
Dow Jones · 03/04 21:15
*Nektar Therapeutics 4Q Loss/Shr 22c >NKTR
Dow Jones · 03/04 21:15
Nektar Therapeutics Q4 23 Earnings Conference Call At 5:00 PM ET
NASDAQ · 03/04 20:04
After-Hours Earnings Report for March 4, 2024 : GTLB, AVAV, NWPX, SFIX, AKYA, TDUP, EOSE, NKTR, DSP, CARA, EKSO, AVAL
NASDAQ · 03/04 19:00
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. The company announced successful testing of its SEAL01 Bitcoin mining chip. BitFuFu Inc. Shares jumped 107% in the mid-day session. Macy's, Inc. And MGE also rose amid strength in the price of Bitcoin.
Benzinga · 03/04 18:29
Nektar Therapeutics: Current report
Press release · 03/04 14:10
More
Webull provides a variety of real-time NKTR stock news. You can receive the latest news about Nektar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NKTR
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.